Prodrugs of 1,4-benzodiazepinone compounds
US-9273075-B2 · Mar 1, 2016 · US
Bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
US12281085B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12281085-B2 |
| Application number | US-202017077857-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 22, 2020 |
| Priority date | May 6, 2018 |
| Publication date | Apr 22, 2025 |
| Grant date | Apr 22, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof;in combination with an additional cancer therapeutic agent, and methods of use thereof for treating diseases and disorders such as cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising a compound represented by the structure of Compound (1): and/or at least one salt thereof in combination with a composition comprising a CDK 4 and 6 inhibitor, sorafenib, regorafenib, venetoclax, vorinostat, or a combination thereof. 2. The composition of claim 1 , wherein said CDK 4 and 6 inhibitor comprises palbociclib, ribociclib, or abemaciclib, or a combination thereof. 3. A method of treating, suppressing or inhibiting adenoid cystic carcinoma (ACC) in a subject in need thereof comprising the step of administering to said subject a first composition comprising a compound represented by the structure of Compound (1): and/or at least one salt thereof, and a second composition comprising a CDK 4 and 6 inhibitor, sorafenib, regorafenib, venetoclax, vorinostat, or a combination thereof and wherein the subject has adenoid cystic carcinoma (ACC). 4. The method of claim 3 , wherein said first composition and/or said second composition is intravenously administered to said subject. 5. The method of claim 3 , wherein said first composition and/or said second composition is orally administered to said subject. 6. The method of claim 3 , wherein said first composition and said second composition are administered together. 7. The method of claim 3 , wherein said first composition and said second composition are administered at separate sites or at separate times. 8. The method of claim 7 , wherein said first composition comprising Formula (I) is administered prior to and then again subsequent to the administration of said second composition. 9. The method of claim 3 , wherein the adenoid cystic carcinoma (ACC) comprises a notch-activating mutation. 10. The method of claim 3 , wherein said CDK 4 and 6 inhibitor comprises palbociclib, ribociclib, or abemaciclib, or a combination thereof.
Assignees
Inventors
Classifications
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
having a heterocyclic ring, e.g. sulfadiazine · CPC title
- A61K31/5513Primary
1,4-Benzodiazepines, e.g. diazepam {or clozapine} · CPC title
Non condensed pyridines; Hydrogenated derivatives thereof · CPC title
Retinoic acids {; Salts thereof} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12281085B2 cover?
- The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof;in combination with an additional cancer therapeutic agent, and methods of use thereof for treating diseases and disorders such as cancer.
- Who is the assignee on this patent?
- Ayala Pharmaceuticals Inc, Bristol Myers Squibb Co, Immunome Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5513. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).